<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589888</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00041116</org_study_id>
    <secondary_id>IRB 668-2006</secondary_id>
    <nct_id>NCT00589888</nct_id>
  </id_info>
  <brief_title>FFA-Induced Hypertension and Endothelial Dysfunction</brief_title>
  <official_title>Free Fatty Acids-Induced Hypertension and Endothelial Dysfunction in Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin resistance has been implicated as the central mechanism in the development of several
      cardiovascular risk factors including hypertension, diabetes, lipid disorders, and
      coagulation disorders. Recent evidence suggests that increased levels of a circulation fat
      (free fatty acids or FFAs) are a leading candidate causing insulin resistance. Our
      preliminary studies in indicate that, in addition to insulin resistance, the infusion of
      Intralipid and heparin to increase FFAs resulted in a significant rise in systolic and
      diastolic blood pressure, impaired endothelial (vascular) function, and increased
      inflammatory markers in obese African Americans with and without diabetes. The effects of FFA
      on insulin action are well established; however, the blood pressure and vascular effects of
      FFAs infusion in obese subjects have not been fully investigated. We hypothesize that
      observed changes in blood pressure are the result of acute endothelial dysfunction, and/or
      increased activation of the autonomic nervous system. No previous studies have attempted to
      determine a dose response effect of increasing FFA on blood pressure. In addition, it is not
      know if increased FFAs by repeated oral fat load results in similar blood pressure than
      intravenous lipid infusion. Accordingly, we propose: 1) a systematic evaluation of the
      effects of increasing FFA levels on blood pressure and endothelial (vascular) function, and
      2) determine the effects of comparable increases in FFA concentration via intravenous
      infusion of Intralipid or by repeated oral fat load on blood pressure, insulin resistance and
      endothelial dysfunction in obese subjects.

      A group of 10 obese normotensive subjects will be admitted to the Grady Clinical Research
      Center or to the Outpatient Research Unit in the Grady Diabetes Clinic on five occasions. In
      four of these admissions, research subjects will receive an 8-hour intravenous infusion, in
      random order, of increasing Intralipid concentration (10 ml, 20 ml, 40 ml per hour) or normal
      saline (40 ml per hour). During the final admission, research subjects will receive an oral
      liquid fat diet every 2 hours for 8-hours. The effect of increased FFAs on blood pressure and
      endothelial (vascular) function via intravenous infusion and via oral fat load therapy will
      be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Systolic Blood Pressure</measure>
    <time_frame>at the end of the 8-hours</time_frame>
    <description>systolic blood pressure change from baseline during an 8-hour normal saline infusion in obese normotensive subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Systolic Blood Pressure</measure>
    <time_frame>at the end of 8 hours</time_frame>
    <description>systolic blood pressure change from baseline during an 8-hour 20% intralipid @ 20cc/hr infusion in obese normotensive subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Systolic Blood Pressure</measure>
    <time_frame>at the end of 8 hours</time_frame>
    <description>BP change from baseline during an 8-hour 20% intralipid @ 40cc/hr infusion in obese normotensive subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Systolic Blood Pressure From Baseline</measure>
    <time_frame>at the end of 8 hours</time_frame>
    <description>systolic blood pressure change from baseline during an oral 32-gram fat load in obese normotensive subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Systolic Blood Pressure</measure>
    <time_frame>at the end of the 8 hours</time_frame>
    <description>systolic blood pressure change from baseline during an oral 64-gram fat load in obese normotensive subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Secondary Outcomes of Interest Are the Effects of Increased FFAs on BP, Endothelial Function and Inflammatory Markers After Oral Fat Load (Chylomicron Pathway) Versus IV Administration of Intralipid Infusion in Obese Normotensive Subjects.</measure>
    <time_frame>Changes in BP assessed every 2 hours during the 8 hours study; Lipid changes assessed every 2 hours during the 8-hour study, and Flow-mediated dilatation, peripheral compliance, PWA, and HRV assessed at 0,4, and 8 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Intralipid 20%@ 20cc/hour</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intralipid 20% IV infusion at 20cc/hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intralipid 20% @ 40cc/hour</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intralipid 20% IV infusion at 40cc/hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline infusion @ 40cc/hour</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline continuous IV infusion at 40cc/hour for 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>32-gram oral fat load</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>32-gram oral fat load once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>64-gram oral fat load</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>64-gram oral fat load once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid 20%</intervention_name>
    <description>Intralipid 20% IV continuous infusion at 20cc/hour for 8 hours</description>
    <arm_group_label>Intralipid 20%@ 20cc/hour</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid 20%</intervention_name>
    <description>Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours</description>
    <arm_group_label>Intralipid 20% @ 40cc/hour</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours</description>
    <arm_group_label>Normal Saline infusion @ 40cc/hour</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>32-gram oral fat load</intervention_name>
    <description>oral liquid fat load prepared by the GCRC every 2 hours for 8 hours.</description>
    <arm_group_label>32-gram oral fat load</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>64-gram oral fat load</intervention_name>
    <description>60-gram oral fat load intake every 2 hours for 8 hours</description>
    <arm_group_label>64-gram oral fat load</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females between the ages of 18 and 65 years.

          -  Definition: obese = BMI â‰¥ 30 kg/m2

          -  Blood pressure &lt; 140/80 mm Hg and no prior history of hypertension

        Exclusion Criteria:

          -  History of hypertension or previous history of antihypertensive drug therapy.

          -  Current tobacco use

          -  Fasting triglyceride levels &gt; 250 mg/dL during the stabilization period.

          -  Liver disease (ALT 2.5x &gt; upper limit of normal), or other significant medical or
             surgical illness, including myocardial ischemia, congestive heart failure, liver
             failure, and infectious processes.

          -  Serum creatinine â‰¥1.5 mg/dL for males, or â‰¥ 1.4 mg/dL for females.

          -  History of drug or alcohol abuse within the last 5 years.

          -  Mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study.

          -  Female subjects are pregnant or breast feeding at time of enrollment into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University SOM/GCRC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gosmanov AR, Smiley DD, Robalino G, Siquiera J, Khan B, Le NA, Patel RS, Quyyumi AA, Peng L, Kitabchi AE, Umpierrez GE. Effects of oral and intravenous fat load on blood pressure, endothelial function, sympathetic activity, and oxidative stress in obese healthy subjects. Am J Physiol Endocrinol Metab. 2010 Dec;299(6):E953-8. doi: 10.1152/ajpendo.00469.2010. Epub 2010 Oct 5.</citation>
    <PMID>20923960</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>January 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <results_first_submitted>March 24, 2014</results_first_submitted>
  <results_first_submitted_qc>June 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2014</results_first_posted>
  <last_update_submitted>June 6, 2014</last_update_submitted>
  <last_update_submitted_qc>June 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>vascular reactivity</keyword>
  <keyword>Elevated blood pressure</keyword>
  <keyword>lipid toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Normal Saline @ 40cc/Hour</title>
          <description>Normal Saline continuous IV infusion at 40cc/hour for 8 hours
0.9% Normal Saline: 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours</description>
        </group>
        <group group_id="P2">
          <title>Intralipid 20% @ 20cc/hr</title>
          <description>Intralipid 20% IV infusion at 20cc/hour
Intralipid 20%: Intralipid 20% IV continuous infusion at 20cc/hour for 8 hours</description>
        </group>
        <group group_id="P3">
          <title>Intralipid 20% @ 40cc/Hour</title>
          <description>Intralipid 20% IV infusion at 40cc/hour
Intralipid 20%: Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours</description>
        </group>
        <group group_id="P4">
          <title>32-gram Oral Fat Load</title>
          <description>32-gram oral fat load
32-gram oral fat load: oral liquid fat load prepared by the GCRC every 2 hours for 8 hours.</description>
        </group>
        <group group_id="P5">
          <title>64-gram Oral Fat Load</title>
          <description>64-gram oral fat load
64-gram oral fat load: 60-gram oral fat load intake every 2 hours for 8 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Normal Saline @ 40cc/Hour</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13">the same 13 patients did each of the 5 arms at 5 different visits</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intralipid 20% @ 20cc/hr</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">the same 13 patients did each of the 5 arms at 5 different visits</participants>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intralipid 20% @ 40cc/Hour</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0">the same 13 patients did each of the 5 arms at 5 different visits</participants>
                <participants group_id="P3" count="13">the same 13 patients did each of the 5 arms at 5 different visits</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>32-gram Oral Fat Load</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0">the same 13 patients did each of the 5 arms at 5 different visits</participants>
                <participants group_id="P4" count="13">the same 13 patients did each of the 5 arms at 5 different visits</participants>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>64-gram Oral Fat Load</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0">the same 13 patients did each of the 5 arms at 5 different visits</participants>
                <participants group_id="P5" count="13">the same 13 patients did each of the 5 arms at 5 different visits</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>obese, healthy subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All participants received all 5 arms in random order:
0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours
Intralipid 20% @ 20cc/hr for 8 hours
Intralipid 20% @ 40cc/Hr for 8 hours
32-gram Oral Fat Load every 2 hours for 8 hours.
64-gram Oral Fat Loadevery 2 hours for 8 hours.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.2" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Systolic Blood Pressure</title>
        <description>systolic blood pressure change from baseline during an 8-hour normal saline infusion in obese normotensive subjects.</description>
        <time_frame>at the end of the 8-hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline @ 40cc/Hour</title>
            <description>Normal Saline continuous IV infusion at 40cc/hour for 8 hours
0.9% Normal Saline: 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure</title>
          <description>systolic blood pressure change from baseline during an 8-hour normal saline infusion in obese normotensive subjects.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Secondary Outcomes of Interest Are the Effects of Increased FFAs on BP, Endothelial Function and Inflammatory Markers After Oral Fat Load (Chylomicron Pathway) Versus IV Administration of Intralipid Infusion in Obese Normotensive Subjects.</title>
        <time_frame>Changes in BP assessed every 2 hours during the 8 hours study; Lipid changes assessed every 2 hours during the 8-hour study, and Flow-mediated dilatation, peripheral compliance, PWA, and HRV assessed at 0,4, and 8 hours</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Systolic Blood Pressure</title>
        <description>systolic blood pressure change from baseline during an 8-hour 20% intralipid @ 20cc/hr infusion in obese normotensive subjects.</description>
        <time_frame>at the end of 8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intralipid @ 20cc/Hour</title>
            <description>Intralipid continuous IV infusion at 20cc/hour for 8 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure</title>
          <description>systolic blood pressure change from baseline during an 8-hour 20% intralipid @ 20cc/hr infusion in obese normotensive subjects.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Systolic Blood Pressure</title>
        <description>BP change from baseline during an 8-hour 20% intralipid @ 40cc/hr infusion in obese normotensive subjects.</description>
        <time_frame>at the end of 8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intralipid @ 20cc/Hour</title>
            <description>Intralipid continuous IV infusion at 20cc/hour for 8 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Systolic Blood Pressure</title>
          <description>BP change from baseline during an 8-hour 20% intralipid @ 40cc/hr infusion in obese normotensive subjects.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Systolic Blood Pressure From Baseline</title>
        <description>systolic blood pressure change from baseline during an oral 32-gram fat load in obese normotensive subjects.</description>
        <time_frame>at the end of 8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral 32-gram Fat Load</title>
            <description>For the low (32 g fat) oral fat load studies, participants received fat with FFA composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Systolic Blood Pressure From Baseline</title>
          <description>systolic blood pressure change from baseline during an oral 32-gram fat load in obese normotensive subjects.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Systolic Blood Pressure</title>
        <description>systolic blood pressure change from baseline during an oral 64-gram fat load in obese normotensive subjects.</description>
        <time_frame>at the end of the 8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral 64-gram Fat Load</title>
            <description>For the high (64 g fat) oral fat load studies, participants received fat with FFA composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Systolic Blood Pressure</title>
          <description>systolic blood pressure change from baseline during an oral 64-gram fat load in obese normotensive subjects.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Normal Saline @ 40cc/Hour</title>
          <description>Normal Saline continuous IV infusion at 40cc/hour for 8 hours
0.9% Normal Saline: 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours</description>
        </group>
        <group group_id="E2">
          <title>Intralipid 20% @ 20cc/hr</title>
          <description>Intralipid 20% IV infusion at 20cc/hour
Intralipid 20%: Intralipid 20% IV continuous infusion at 20cc/hour for 8 hours</description>
        </group>
        <group group_id="E3">
          <title>Intralipid 20% @ 40cc/Hour</title>
          <description>Intralipid 20% IV infusion at 40cc/hour
Intralipid 20%: Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours</description>
        </group>
        <group group_id="E4">
          <title>32-gram Oral Fat Load</title>
          <description>32-gram oral fat load
32-gram oral fat load: oral liquid fat load prepared by the GCRC every 2 hours for 8 hours.</description>
        </group>
        <group group_id="E5">
          <title>64-gram Oral Fat Load</title>
          <description>64-gram oral fat load
64-gram oral fat load: 60-gram oral fat load intake every 2 hours for 8 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>indigestion</sub_title>
                <description>temporary symptoms of reflux after ingesting the meal; no permanent sequelae or discontinuation</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>venous irritation</sub_title>
                <description>temporary irritation of vein towards the end of the 8-hour infusion; no permanent sequelae or discontinuation</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Guillermo Umpierrez, MD</name_or_title>
      <organization>Emory Univ SOM</organization>
      <phone>4047781665</phone>
      <email>geumpie@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

